New York State
Ibogaine Research Bill
URGENT- Sign the NYS Petition for January 2026
“Ibogaine is a Solution for War on Drugs”
Join our Campaign for KRFI Questors Private Public Sector Partnership and advocate for the NYS Ibogaine Research Bill for Access for Benefit Sharing for IP and for the enforcement of the Drug Supply Chain Security Act.
Pledge and sign up for the NYS Ibogaine Clinical Research Bill for Opioid and Substance Use Treatment for Veterans, TBI, PTSD, including Tribal Opioid/Substance Response to Health Equity. Send your petition signature and a letter requesting NYS Governor Hochul and Commissioner Cunningham of the NYS Office of Addiction Services and Supports (OASAS) to sign the bill by January 2026, to meet the NYS Senate and Assembly deadline.
Write to Governor.Hochul@exec.ny.gov
Write to: Chinazo.Cunningham@ny.gov
​
Bi-Partisan Senate Bill S1817
​
​
Knowledge Recovery Foundation/Institute is a Public Benefit 501c3 Not for Profit Organization engaged in Questors science and technologies, and Private Public Sector Partnership Consortium operated by the Global Mental Health Security Task Force Committee to establish a global community to support the current opioid and substance endemic in the USA.
​
US Bipartisan Bill for Ibogaine Clinical Research Act
​
Currently, Texas has Bipartisan bill for has been passed in June of 2025 with $50Mn funds for Ibogaine Clinical Research Act. Bipartisan bill in New York State is planned to be launched FDA Investigative New Drug development of Ibogaine for Opioid Use Disorder and Substance Use Disorder including Traumatic Brain Injuries and PTSD.
​
New York State’s Opioid abatement settlement fund is $12 Bn USD from the Opioid Settlement fund managed by OASAS, NYS. Currently KRFI is campaigning for the signatures for the Bi-partisan Bill for Ibogaine Clinical Research Act in the Senatorial Assembly in January of 2026.
​
Please join us and sign the petition for Bipartisan bill for in NYS to pass in Jary of 2026 with $300Mn funds for Ibogaine Clinical Research Act. Bipartisan bill in New York State is planned to be launched FDA Investigative New Drug development of Ibogaine for Opioid Use and Substance Use Disorder.
​